These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26542743)

  • 1. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
    Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
    Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
    Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
    Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
    Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
    Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.
    Munch-Petersen HD; Rasmussen BB; Balslev E
    APMIS; 2014 Sep; 122(9):750-4. PubMed ID: 24372587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Human Epidermal Growth Factor Receptor 2 (HER2) Retesting of Histologic Grade 3 Invasive Breast Carcinomas.
    Gologorsky R; Cureton E; Shim V
    Perm J; 2019; 23():18-088. PubMed ID: 30624197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
    Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
    Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
    Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
    J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens.
    Hariri N; Hasteh F; Walavalkar V; Roma AA; Fadare O
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):1-7. PubMed ID: 28549033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?
    Bethune GC; Mullen JB; Chang MC
    Am J Clin Pathol; 2013 Oct; 140(4):588-92. PubMed ID: 24045558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
    Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
    Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
    Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
    Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
    Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
    Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines.
    Vergara-Lluri ME; Moatamed NA; Hong E; Apple SK
    Mod Pathol; 2012 Oct; 25(10):1326-32. PubMed ID: 22699517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.